Advertisement
U.S. markets close in 1 hour 22 minutes

Solid Biosciences Inc. (SLDB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
13.18-1.07 (-7.51%)
As of 02:38PM EDT. Market open.
Full screen
Loading interactive chart...
  • Investor's Business Daily

    How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback

    Solid Biosciences is shrugging off several messy years in gene therapy development. The biotech stock has gotten a triple-digit boost.

  • GlobeNewswire

    Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium

    CHARLESTOWN, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, and Gabriel Brooks, M.D., Chief Medical Officer, will present at Cantor’s Virtual Muscular Dystrophy Symposium on Tuesday, April 2, 2024, at 8:15 am ET. A live webcast of the presentation will be available on the Events page of the I

  • GlobeNewswire

    Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results

    — Company ends 2023 with approximately $123.6 million in cash and investments. Combined with gross proceeds from $108.9 million private placement in January, Solid has anticipated cash runway into 2026 — — FDA cleared IND and granted Fast Track Designation and Orphan Drug Designation for Duchenne muscular dystrophy (Duchenne) gene therapy candidate SGT-003 with patient dosing in Phase 1/2 trial expected Q2 2024 — — Company entered into non-exclusive licensing agreement for use of its proprietary